Peter Høngaard Andersen

Dr. Peter Høngaard Andersen holds a B.Sc. in Chemistry, an M.Sc. in Biochemistry is an M.D. and has many years of experience and a broad network from his previous positions within the Life Science and biotech industries. Dr. Høngaard Andersen also has many years of experience in pharmaceutical research and development from the pharmaceutical industry: 14 years at Novo Nordisk in CNS, neuroendocrinology, women’s health, and type-2 diabetes and 15 years at Lundbeck in CNS pharmaceutical research and early development. Dr. Høngaard Andersen has been involved in the research and development of several pharmaceuticals on the market (e.g. Norditropine, Simplex, Victoza, Trintellix / Brintellix, Cipralex).

Dr. Høngaard Andersen has been a founder or co-founder of several biotech companies, including Acadia Pharmaceuticals, Zealand Pharma, Glycom, Serendex, Epitherapeutics, and Prexton Pharmaceuticals. Dr. Høngaard Andersen was involved in the Innovative Medicines Initiative (IMI) from its inception in 2003 and served as Chairman of the industry side of IMI from 2009–2014. In addition, Dr. Høngaard Andersen is a Venture Partner in Ysios Capital and a member of the Advisory Board in Eir Ventures.